Protocols · Longevity & Mitochondrial
MOTS-c Mitochondrial Function Protocol
Mitochondrial-Derived Peptide | Insulin Sensitivity & Exercise Capacity
Typical Dose
5–20 mg
SC, 2–3x weekly; titrated by phase and body weight
Route
Subcutaneous
Abdomen, thigh, or posterior arm; rotate sites
Cycle
12 weeks on / 4–8 off
Typically 2 cycles per year with lab reassessment
Storage
Refrigerate 2–8°C
Lyophilized stable at room temp; reconstituted vials refrigerated up to 28 days
Patient version available. Share ?view=patient with patients for the plain-language handout.
Overview
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome that functions as a metabolic regulator linking mitochondrial signaling to nuclear gene expression. This protocol targets patients with early metabolic dysfunction, age-related decline in exercise capacity, insulin resistance without overt diabetes, and individuals seeking to optimize mitochondrial biogenesis as part of a longevity strategy.
The ideal candidate is typically 35–70 years old with one or more of: HOMA-IR > 2.0, declining VO2max relative to age-predicted norms, visceral adiposity with normal BMI ("TOFI" phenotype), fatigue with documented mitochondrial dysfunction markers, or metabolic syndrome features without contraindicating comorbidities. The protocol uses two MOTS-c strengths (10 mg and 40 mg vials) to allow titration from a conservative induction dose to a maintenance dose suited to body weight and clinical response.
Functionally, the stack delivers a single agent at two dose tiers rather than a combination, with the goal of activating AMPK-dependent metabolic adaptation, improving glucose disposal, restoring mitochondrial substrate flexibility, and supporting exercise-induced adaptations that decline with age.
Key Benefits
Improves insulin sensitivity (HOMA-IR reductions of 15–30% in responders), enhances exercise capacity, and supports mitochondrial biogenesis via AMPK activation. Best suited to early metabolic dysfunction and age-related decline in metabolic flexibility.
Mechanism of Action
16-amino-acid mitochondrial-derived peptide that activates AMPK, drives PGC-1α-mediated mitochondrial biogenesis, and translocates to the nucleus under metabolic stress to coregulate adaptive gene expression — improving GLUT4 translocation and skeletal muscle glucose uptake.
Molecular Information
Weight
~2174 Da
Length
16 amino acids
Type
Mitochondrial-derived peptide (MDP)
Amino Acid Sequence
MRWQEMGYIFYPRKLR
* Encoded within the 12S rRNA region of the mitochondrial genome.
Pharmacokinetics
Research Indications
Insulin SensitizationEMERGING
HOMA-IR Reduction
15–30% reductions in responders by week 8
GLUT4 Translocation
Enhances insulin-independent skeletal muscle glucose uptake
Prediabetes
HbA1c reductions of 0.1–0.4% in patients starting 5.6–6.4%
Exercise CapacityEMERGING
Exercise Mimetic-Adjunct
Potentiates exercise-induced adaptations in preclinical models
Recovery
Subjective improvement in between-session recovery by week 4
Substrate Flexibility
Improves fatty acid oxidation and metabolic switching
Longevity & Mitochondrial FunctionMIXED
Mitochondrial Biogenesis
AMPK/PGC-1α activation drives new mitochondrial synthesis
Age-Related Decline
Endogenous MOTS-c levels decline with age and inversely correlate with insulin resistance
Lifespan Claims
Hypothesis-generating only — no human RCT evidence
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Induction (Weeks 1–2) | 5 mg | 2–3x weekly | SC |
| Induction (Weeks 3–4) | 10 mg | 2x weekly | SC |
| Maintenance (<80 kg) | 10 mg | 2x weekly | SC |
| Maintenance (80–100 kg) | 15 mg | 2x weekly | SC |
| Maintenance (>100 kg) | 20 mg | 2x weekly | SC |
| Pre-Exercise Timing | Scheduled dose | 30–60 min pre-training | SC |
Timing · Pre-exercise dosing on training days appears to maximize benefit based on preclinical mechanistic data. Rotate injection sites and reconstitute per compounding pharmacy specifications.
Peptide Interactions
- Insulin— Additive hypoglycemia risk; preemptive dose reduction may be warrantedMONITOR
- Metformin— Pharmacodynamic overlap on AMPK; monitor for additive GI effects and hypoglycemiaMONITOR
- Sema— Overlapping metabolic effects; no documented interaction but monitor glucose closelyMONITOR
- Tirz— Overlapping metabolic effects; close glucose monitoring advisedMONITOR
- Reta— Overlapping metabolic effects; close glucose monitoring advisedMONITOR
- Sulfonylureas— High hypoglycemia risk without dose adjustment capabilityAVOID
- BPC-157— No mechanistic conflict; often paired for recovery supportCOMPATIBLE
- CJC-1295 / Ipamorelin— Complementary effects on body composition and metabolic healthSYNERGISTIC
- 5-Amino-1MQ— Complementary mitochondrial and metabolic flexibility supportSYNERGISTIC
How to Reconstitute
- 1
Allow lyophilized MOTS-c vial and bacteriostatic water to reach room temperature.
- 2
Sanitize both vial stoppers with isopropyl alcohol swabs.
- 3
Draw 2 mL of bacteriostatic water into a sterile syringe (typical for 10 mg vial; adjust for 40 mg per compounding spec).
- 4
Inject the bacteriostatic water slowly down the inside wall of the peptide vial — do not spray directly onto the powder.
- 5
Gently swirl the vial to dissolve. Do not shake — agitation can denature the peptide.
- 6
Allow the solution to fully clarify (typically 30–60 seconds). Inspect for clarity and absence of particulates.
- 7
Label the vial with reconstitution date and concentration (e.g., 5 mg per 1 mL for 10 mg vial in 2 mL diluent).
- 8
Store reconstituted vial refrigerated at 2–8°C.
- 9
Draw prescribed dose into an insulin syringe; expel air bubbles.
- 10
Cleanse injection site (abdomen, thigh, or posterior arm) with alcohol and inject subcutaneously at 45–90°.
- 11
Rotate injection sites between administrations to minimize local reactions.
- 12
Discard reconstituted vial after 28 days or per compounding pharmacy guidance.
Quality Indicators
Clear Solution
Reconstituted MOTS-c should be clear and colorless with no visible particles.
Mild Injection Site Reaction
Erythema or mild discomfort is common and self-limited; rotate sites.
Transient Fatigue Week 1–2
Flu-like sensation likely reflects AMPK-mediated metabolic shift; typically resolves.
Cloudy or Discolored Solution
Discard the vial — indicates degradation or contamination.
What to Expect
Week 1–2: possible transient fatigue or flu-like sensation as AMPK signaling shifts metabolism
Week 4: improved energy, reduced post-meal somnolence, better workout recovery
Week 6: early measurable reductions in fasting insulin and HOMA-IR in responders
Week 8: 15–30% HOMA-IR reductions; improved CGM glucose variability and time-in-range
Week 8: improved exercise tolerance and subjective recovery
Week 12: HbA1c reductions of 0.1–0.4% in prediabetic range
Week 12: body composition improvements, particularly visceral adiposity, with concurrent resistance training
~20–30% of patients are non-responders — consider discontinuation if no objective marker improvement by week 12
Response is better with structured resistance + zone 2 cardio, adequate protein, and sleep optimization
Side Effects & Safety
- Injection site erythema or mild discomfort
- Transient fatigue or flu-like sensation in first 1–2 weeks
- Mild hypoglycemia symptoms (especially with concomitant glucose-lowering therapy)
- Headache
- Occasional nausea
- Variable appetite changes (theoretical)
When to Stop & Call Provider
- Symptomatic hypoglycemia (sweating, tremor, confusion)
- Persistent severe fatigue beyond week 2
- Allergic reaction (rash, urticaria, swelling, dyspnea)
- New or worsening abdominal pain
- Unexplained tachycardia or palpitations
References
Lee C et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Foundational paper demonstrating MOTS-c activates AMPK, improves insulin sensitivity, and prevents high-fat-diet-induced obesity in mice.
Reynolds JC et al. — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Demonstrates MOTS-c enhances exercise capacity and recapitulates exercise-induced adaptations; endogenous levels rise with exercise and decline with age.
Kim SJ et al. — Mitochondrially derived peptides as novel regulators of metabolism
Comprehensive review of MDP biology including MOTS-c nuclear translocation, AMPK signaling, and folate-methionine cycle modulation.
Ramanjaneya M et al. — Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance
Human biomarker study showing endogenous MOTS-c levels correlate inversely with insulin resistance and BMI — supporting exogenous administration rationale.